C57BL/6JCya-Brafem1flox/Cya
Common Name
Braf-flox
Product ID
S-CKO-00808
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-109880-Braf-B6J-VA
Status
When using this mouse strain in a publication, please cite “Braf-flox Mouse (Catalog S-CKO-00808) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Basic Information
Strain Name
Braf-flox
Strain ID
CKOCMP-109880-Braf-B6J-VA
Gene Name
Product ID
S-CKO-00808
Gene Alias
B-raf, Braf2, Braf-2, C230098H17, D6Ertd631e, 9930012E13Rik
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
Chr 6
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000002487
NCBI RefSeq
NM_139294
Target Region
Exon 5
Size of Effective Region
~0.6 kb
Overview of Gene Research
BRAF, short for B-Raf proto-oncogene, encodes a cytoplasmic serine/threonine kinase. It plays a key role in regulating the mitogen-activated protein kinase (MAPK) signal transduction pathway, which is crucial for cellular physiological activities such as proliferation, differentiation, apoptosis, and senescence [3,4].
BRAF is frequently mutated in several cancers. In melanoma, it is one of the most frequently mutated oncogenes, with around 40-50% of melanomas having BRAF mutations, mostly at codon 600 (notably V600E), leading to constitutive activation of the BRAF/MEK/ERK (MAPK) pathway [1,5]. In colorectal cancer (CRC), about 10% of patients have BRAF mutations, which are associated with poor response to chemotherapy and prognosis [2]. In non-small cell lung cancer (NSCLC), BRAF mutations occur in 1%-2% of adenocarcinoma cases, often in never-smokers and women [6]. BRAF-targeted therapies like BRAF inhibitors have shown promise in treating BRAF-mutated cancers, but resistance mechanisms frequently develop [1,2,6,7,8].
In conclusion, BRAF is a critical regulator in the MAPK pathway, and its mutations are closely associated with the development and prognosis of multiple cancers. The study of BRAF-mutated models has provided insights into cancer pathogenesis and therapeutic strategies, highlighting the importance of understanding BRAF-related mechanisms for better cancer treatment.
References：
1. Castellani, Giorgia, Buccarelli, Mariachiara, Arasi, Maria Beatrice, Lintas, Carla, Tabolacci, Claudio. 2023. BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. In Cancers, 15, . doi:10.3390/cancers15164026. https://pubmed.ncbi.nlm.nih.gov/37627054/
2. Aiman, Wajeeha, Ali, Muhammad Ashar, Jumean, Samer, Guron, Gunwant, Shaaban, Hamid. 2023. BRAF Inhibitors in BRAF-Mutated Colorectal Cancer: A Systematic Review. In Journal of clinical medicine, 13, . doi:10.3390/jcm13010113. https://pubmed.ncbi.nlm.nih.gov/38202120/
3. Loo, Eric, Khalili, Parisa, Beuhler, Karen, Siddiqi, Imran, Vasef, Mohammad A. . BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry. In Applied immunohistochemistry & molecular morphology : AIMM, 26, 709-713. doi:10.1097/PAI.0000000000000516. https://pubmed.ncbi.nlm.nih.gov/29271794/
4. Liu, Haotian, Nazmun, Nahar, Hassan, Shafat, Liu, Xinyue, Yang, Jilong. 2020. BRAF mutation and its inhibitors in sarcoma treatment. In Cancer medicine, 9, 4881-4896. doi:10.1002/cam4.3103. https://pubmed.ncbi.nlm.nih.gov/32476297/
5. Pelosi, Elvira, Castelli, Germana, Testa, Ugo. 2024. Braf-Mutant Melanomas: Biology and Therapy. In Current oncology (Toronto, Ont.), 31, 7711-7737. doi:10.3390/curroncol31120568. https://pubmed.ncbi.nlm.nih.gov/39727691/
6. Yan, Ningning, Guo, Sanxing, Zhang, Huixian, Shen, Shujing, Li, Xingya. 2022. BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective. In Frontiers in oncology, 12, 863043. doi:10.3389/fonc.2022.863043. https://pubmed.ncbi.nlm.nih.gov/35433454/
7. Foth, Mona, McMahon, Martin. 2021. Autophagy Inhibition in BRAF-Driven Cancers. In Cancers, 13, . doi:10.3390/cancers13143498. https://pubmed.ncbi.nlm.nih.gov/34298710/
8. Alqathama, Aljawharah. 2020. BRAF in malignant melanoma progression and metastasis: potentials and challenges. In American journal of cancer research, 10, 1103-1114. doi:. https://pubmed.ncbi.nlm.nih.gov/32368388/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.